{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:52:49Z","timestamp":1776707569981,"version":"3.51.2"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.jhep.2008.10.024","type":"journal-article","created":{"date-parts":[[2008,12,26]],"date-time":"2008-12-26T04:26:01Z","timestamp":1230265561000},"page":"584-591","source":"Crossref","is-referenced-by-count":53,"title":["Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: An open label trial"],"prefix":"10.1016","volume":"50","author":[{"given":"Praveen","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barjesh Chander","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiv Kumar","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2008.10.024_bib1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJM199202203260802","article-title":"A randomized trial of prednisolone in patients with severe alcoholic hepatitis","volume":"326","author":"Ramond","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2008.10.024_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM196607142750201","article-title":"Prognosis in acute liver disease of the alcoholic patient","volume":"275","author":"Hardison","year":"1966","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2008.10.024_bib3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/0016-5085(95)90449-2","article-title":"Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats","volume":"108","author":"Lopez-Talavera","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2008.10.024_bib4","first-page":"1616","article-title":"Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats","volume":"23","author":"Lopez-Talavera","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.10.024_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-2007-1007110","article-title":"Cytokines in alcoholic liver disease","volume":"19","author":"McClain","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2008.10.024_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.7326\/0003-4819-112-12-917","article-title":"Increased plasma tumor necrosis factor in severe alcoholic hepatitis","volume":"112","author":"Bird","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2008.10.024_bib7","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/00042737-200412000-00023","article-title":"Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study","volume":"16","author":"Alvarez","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2008.10.024_bib8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/hep.1840120331","article-title":"Corticosteroid therapy of alcoholic hepatitis: how many studies will it take?","volume":"12","author":"Reynolds","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.10.024_bib9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7326\/0003-4819-113-4-299","article-title":"Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials","volume":"113","author":"Imperiale","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2008.10.024_bib10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0168-8278(01)00289-6","article-title":"Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH","volume":"36","author":"Mathurin","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2008.10.024_bib11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0168-8278(00)80219-6","article-title":"Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids","volume":"32","author":"Ta\u00efeb","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2008.10.024_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0168-8278(02)00442-7","article-title":"Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis","volume":"38","author":"Tilg","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2008.10.024_bib13","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/gut.52.8.1182","article-title":"Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis","volume":"52","author":"Mookerjee","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2008.10.024_bib14","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2008.10.024_bib15","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2008.10.024_bib16","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"Foie-Alcool group of the Association Fran\u00e7aise pour l\u2019Etude du Foie. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.10.024_bib17","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.21607","article-title":"The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids","volume":"45","author":"Louvet","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.10.024_bib18","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0168-8278(01)00190-8","article-title":"Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood","volume":"35","author":"Spahr","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2008.10.024_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0168-8278(02)00230-1","article-title":"Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study","volume":"37","author":"Spahr","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2008.10.024_bib20","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.3748\/wjg.v12.i43.6909","article-title":"Current concepts and controversies in the treatment of alcoholic hepatitis","volume":"12","author":"Rongey","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2008.10.024_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/hep.20344","article-title":"Infliximab and alcoholic hepatitis","volume":"40","author":"Mookerjee","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.10.024_bib22","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1053\/j.gastro.2008.08.057","article-title":"A randomized, double-blinded, placebo-controlled multi-center trial of etanercept in the treatment of alcoholic hepatitis","volume":"135","author":"Boetticher","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2008.10.024_bib23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/alcalc\/33.6.606","article-title":"Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis","volume":"33","author":"Hanck","year":"1998","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.jhep.2008.10.024_bib24","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2008.10.024_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2036.2007.03553.x","article-title":"Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease","volume":"27","author":"Theis","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2008.10.024_bib26","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1053\/jhep.2003.09038","article-title":"Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone","volume":"38","author":"Mathurin","year":"2003","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827808007927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827808007927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,23]],"date-time":"2018-12-23T04:59:40Z","timestamp":1545541180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827808007927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0168827808007927"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2008.10.024","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}